Major investor Triple Frond Partners sold its entire position in genetics sequencing leader Illumina Inc. (ILMN) during the second quarter of 2026. The firm divested all 306,460 shares, a holding previously valued at approximately $37.8 million. This significant stake had constituted nearly 4% of Triple Frond's reported portfolio, and its complete liquidation marks a notable change in strategy for the investment firm known for its concentrated, long-term holdings.
This transaction was disclosed in a mandatory 13F filing dated August 13, 2026, which details the firm's holdings as of June 30, 2026. The sale occurred at an unknown time during a quarter where Illumina reported strong financial results, beating analyst expectations and raising its full-year revenue guidance. No public comments from Triple Frond explaining the reason for the exit have been identified.